FDA officials said that the draft guidance is meant to address recommendations from two reports on the agency's response to COVID-19.
The TissueCypher assay is designed to identify patients with Barrett's esophagus who are at risk of progressing to esophageal cancer.
NEW YORK – Canadian point-of-care imaging firm MolecuLight on Monday announced that it has secured a $27.5 million investment from asset management firm Hayfin Capital Management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback